Hypereosinophilic Syndrome

The corrected data help report baseline disease severity in the benralizumab trial more accurately. Correcting prior biologic therapy percentages is presented as important for characterizing the treatment history of the trial population. The corrections improve reporting of baseline disease severity in the benralizumab trial. The total trial population for the HES study was 133 patients with a corrected baseline median eosinophil count of 1,100.0 cells. The total trial population for the HES study was 133 patients, with a corrected median eosinophil count of 1,100.0 cells (range 60–20,910). The total HES trial population (N = 133) had a corrected baseline median eosinophil count of 1,100.0 cells with a range of 60–20,910. The total trial population for the HES study was 133 patients. The total trial population for this HES study was 133 participants. The benralizumab HES trial enrolled 133 total participants. Baseline eosinophil counts in HES trials directly influence the interpretation of treatment efficacy. The total trial population for the HES study consisted of 133 participants. The total trial population for the HES study comprised 133 participants. The phase 3 HES trial enr…